Akero Therapeutics Inc - Asset Resilience Ratio
Akero Therapeutics Inc (AKRO) has an Asset Resilience Ratio of 55.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Akero Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Akero Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AKRO current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Akero Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Akero Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $561.79 Million | 55.87% |
| Total Liquid Assets | $561.79 Million | 55.87% |
Asset Resilience Insights
- Very High Liquidity: Akero Therapeutics Inc maintains exceptional liquid asset reserves at 55.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Akero Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Akero Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Akero Therapeutics Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Akero Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.78% | $402.84 Million | $825.89 Million | -5.65pp |
| 2023-12-31 | 54.42% | $315.80 Million | $580.27 Million | +25.91pp |
| 2022-12-31 | 28.52% | $101.68 Million | $356.57 Million | +9.20pp |
| 2021-12-31 | 19.32% | $37.77 Million | $195.55 Million | -10.37pp |
| 2020-12-31 | 29.69% | $81.14 Million | $273.34 Million | -22.16pp |
| 2019-12-31 | 51.85% | $71.61 Million | $138.12 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $77.15 Million | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more